Compare Travere Therapeutics Inc. Common Stock (TVTX) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs VNET Group Inc — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while VNET Group Inc trades at $4.54 (market cap $1.49B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 3.3× VNET Group Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and VNET Group Inc for 16 Days on average.
| TVTX | VNET | |
|---|---|---|
Market Cap | $4.88B | $1.49B |
Volume | 1,668,577 | 3,619,133 |
Sector | Health | Technology |
52-Week High | $67.52 | $14.03 |
52-Week Low | $26.79 | $4.49 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $5.01B | $5.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
VNET trades at $5.26, down 1.13% today, and has hit new 52-week lows recently. The technical outlook is bearish, with moving averages signaling a downtrend. Fundamentally, the company reported a net loss of $256.77 million in 2025, with a negative net income margin of -22.18%, though revenue grew to $9.95 billion. Recent news includes a strategic investment closing and a cooperation agreement with CATL, providing some positive catalysts amid financial challenges.
The outlook remains cautious due to persistent losses and high leverage, but analyst sentiment is moderately positive with a 'Buy' consensus. Key risks include balance sheet strain and competitive pressures in the data center market. Investment opportunity hinges on execution of growth initiatives and improvement in profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
